Privia Health Group, Inc. $PRVA Shares Purchased by Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB boosted its stake in shares of Privia Health Group, Inc. (NASDAQ:PRVA) by 113.0% during the 3rd quarter, Holdings Channel.com reports. The firm owned 194,189 shares of the company’s stock after acquiring an additional 103,000 shares during the period. Rhenman & Partners Asset Management AB’s holdings in Privia Health Group were worth $4,835,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the stock. Van Berkom & Associates Inc. boosted its stake in shares of Privia Health Group by 30.1% in the 3rd quarter. Van Berkom & Associates Inc. now owns 3,774,565 shares of the company’s stock valued at $93,987,000 after buying an additional 873,344 shares during the period. Vanguard Group Inc. increased its stake in shares of Privia Health Group by 5.3% during the third quarter. Vanguard Group Inc. now owns 12,098,933 shares of the company’s stock worth $301,263,000 after buying an additional 607,447 shares during the period. Qube Research & Technologies Ltd raised its holdings in Privia Health Group by 93.3% in the second quarter. Qube Research & Technologies Ltd now owns 609,278 shares of the company’s stock valued at $14,013,000 after acquiring an additional 294,101 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in Privia Health Group in the second quarter worth approximately $6,219,000. Finally, First Trust Advisors LP grew its holdings in Privia Health Group by 482.7% during the 2nd quarter. First Trust Advisors LP now owns 279,005 shares of the company’s stock worth $6,417,000 after acquiring an additional 231,125 shares in the last quarter. Institutional investors and hedge funds own 94.48% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on PRVA. Stephens restated an “overweight” rating and issued a $32.00 price objective on shares of Privia Health Group in a report on Thursday, December 4th. Truist Financial increased their target price on Privia Health Group from $31.00 to $33.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Wolfe Research set a $31.00 price target on Privia Health Group in a research note on Tuesday, January 6th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Privia Health Group in a report on Monday, December 29th. Finally, Citigroup dropped their price objective on Privia Health Group from $34.00 to $32.00 and set a “buy” rating on the stock in a report on Tuesday, March 3rd. Thirteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $31.00.

Privia Health Group Price Performance

Shares of NASDAQ:PRVA opened at $23.27 on Friday. Privia Health Group, Inc. has a 12 month low of $18.77 and a 12 month high of $26.51. The firm has a market capitalization of $2.88 billion, a P/E ratio of 136.88, a P/E/G ratio of 1.56 and a beta of 0.82. The company’s fifty day moving average price is $23.04 and its 200 day moving average price is $23.57.

Privia Health Group (NASDAQ:PRVA) last issued its quarterly earnings data on Thursday, February 26th. The company reported $0.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.21. Privia Health Group had a return on equity of 3.06% and a net margin of 1.08%.The company had revenue of $541.17 million for the quarter, compared to analyst estimates of $516.61 million. During the same quarter last year, the company posted $0.21 earnings per share. The business’s quarterly revenue was up 17.4% compared to the same quarter last year. On average, sell-side analysts anticipate that Privia Health Group, Inc. will post 0.14 EPS for the current year.

Insider Buying and Selling

In related news, Director Matthew Shawn Morris sold 16,550 shares of the firm’s stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $25.00, for a total transaction of $413,750.00. Following the transaction, the director owned 68,188 shares in the company, valued at $1,704,700. This trade represents a 19.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO David Mountcastle sold 23,887 shares of Privia Health Group stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $25.03, for a total value of $597,891.61. Following the transaction, the chief financial officer directly owned 172,909 shares in the company, valued at approximately $4,327,912.27. This trade represents a 12.14% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 74,930 shares of company stock worth $1,874,410 in the last 90 days. 10.70% of the stock is currently owned by company insiders.

Privia Health Group Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.